合并危险因素的高钾血症诊治进展

doi:10.12114/j.issn.1007-9572.2022.0312

摘要/Abstract

摘要： 高钾血症是临床上的常见问题，其发生的危险因素包括患有肾脏疾病、心血管疾病、糖尿病以及服用影响血钾的药物等。主要表现为心脏和神经肌肉症状，也可导致严重的心律失常。治疗上需以血钾水平和临床表现的严重程度为指导来选择药物或透析治疗。近年来涌现出多种新型口服降血钾药物，有望改变高钾血症的治疗模式。本文结合文献，对合并危险因素的高钾血症的流行病学、诊断、发病原因、预防和治疗等进行综述，以期为合并危险因素的高钾血症的相关诊疗提供理论依据。

关键词: 高钾血症, 危险因素, 诊断, 治疗, 综述

Abstract:

Hyperkalemia is a common clinical problem, and risk factors for its occurrence include having kidney disease, cardiovascular disease, diabetes, and taking medications that affect serum potassium. Mainly presenting with cardiac and neuromuscular symptoms, it can also lead to serious cardiac arrhythmias. Therapeutically, the choice of drug or dialysis treatment should be guided by the serum potassium level and the severity of clinical manifestations. Multiple novel oral potassium lowering drugs have emerged in recent years, promising to change the treatment paradigm of hyperkalaemia. In this paper, the epidemiology, diagnosis, cause, prevention, and treatment of hyperkalemia associated with comorbid risk factors were reviewed in combination with the literature, in order to provide a theoretical basis for the related diagnosis and treatment of hyperkalemia associated with combined risk factors.

Key words: Hyperkalemia, Risk factors, Diagnosis, Treatment, Review

罗培艺,马良,苟慎菊. 合并危险因素的高钾血症诊治进展[J]. 中国全科医学, 2022, 25(36): 4587-4594. DOI: 10.12114/j.issn.1007-9572.2022.0312.
LUO Peiyi,MA Liang,GOU Shenju. Progress in Diagnosis and Treatment of Hyperkalemia with Comorbid Risk Factors[J]. Chinese General Practice, 2022, 25(36): 4587-4594. DOI: 10.12114/j.issn.1007-9572.2022.0312.

参考文献 49

[1]	CLASE C M, CARRERO J J, ELLISON D H, et al. Potassium homeostasis and management of dyskalemia in kidney diseases：conclusions from a Kidney Disease：improving Global Outcomes （KDIGO） Controversies Conference[J]. Kidney Int，2020，97(1):42-61. DOI：10.1016/j.kint.2019.09.018.
[2]	NASH D M, MARKLE-REID M, BRIMBLE K S, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults：a population-based study[J]. Nephrol Dial Transplant，2019，34(7):1145-1154. DOI：10.1093/ndt/gfz062.
[3]	边佳明，左力，赵厚宇，等. 中国门诊患者高钾血症分布及诊疗现状的流行病学研究[J]. 中国血液净化，2020，19(11):726-729,746. DOI：10.3969/j.issn.1671-4091.2020.11.002.
[4]	KASHIHARA N, KOHSAKA S, KANDA E, et al. Hyperkalemia in real-world patients under continuous medical care in Japan[J]. Kidney Int Rep，2019，4(9):1248-1260. DOI：10.1016/j.ekir.2019.05.018.
[5]	BIANCHI S, AUCELLA F, DE NICOLA L, et al. Management of hyperkalemia in patients with kidney disease：a position paper endorsed by the Italian Society of Nephrology[J]. J Nephrol，2019，32(4):499-516. DOI：10.1007/s40620-019-00617-y.
[6]	中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J]. 中华肾脏病杂志，2020，36(10):781-792. DOI：10.3760/cma.j.cn441217-20200721-00139.
[7]	BETTS K A, WOOLLEY J M, MU F, et al. The prevalence of hyperkalemia in the United States[J]. Curr Med Res Opin，2018，34(6):971-978. DOI：10.1080/03007995.2018.1433141.
[8]	POLLACK K, MANNING K R, BALASSONE J, et al. Hyperkalaemia in the emergency department：Epidemiology，management and monitoring of treatment outcomes[J]. Emerg Med Australas，2022. DOI：10.1111/1742-6723.13971.
[9]	GASPARINI A, EVANS M, BARANY P, et al. Plasma potassium ranges associated with mortality across stages of chronic kidney disease：the Stockholm CREAtinine Measurements（SCREAM） project[J]. Nephrol Dial Transplant，2019，34(9):1534-1541. DOI：10.1093/ndt/gfy249.
[10]	EINHORN L M, ZHAN M, HSU V D, et al. The frequency of hyperkalemia and its significance in chronic kidney disease[J]. Arch Intern Med，2009，169(12):1156-1162. DOI：10.1001/archinternmed.2009.132.
[11]	WANG A Y M. Optimally managing hyperkalemia in patients with cardiorenal syndrome[J]. Nephrol Dial Transplant，2019，34(Suppl 3):iii36-44. DOI：10.1093/ndt/gfz225.
[12]	ROSANO G M C, TAMARGO J, KJELDSEN K P, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors：coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology[J]. Eur Heart J Cardiovasc Pharmacother，2018，4(3):180-188. DOI：10.1093/ehjcvp/pvy015.
[13]	KOVESDY C P, MATSUSHITA K, SANG Y Y, et al. Serum potassium and adverse outcomes across the range of kidney function：a CKD Prognosis Consortium meta-analysis[J]. Eur Heart J，2018，39(17):1535-1542. DOI：10.1093/eurheartj/ehy100.
[14]	梅长林，陈晓农，郝传明，等. 慢性肾脏病高钾血症风险评估及管理专家建议（2020版）[J]. 中华医学杂志，2020，100(44):3489-3493. DOI：10.3760/cma.j.cn112137-20200918-02669.
[15]	中国医师协会心血管内科医师分会心力衰竭学组，中国心力衰竭患者高钾血症管理专家共识工作组. 中国心力衰竭患者高钾血症管理专家共识[J]. 中华医学杂志，2021，101(42):3451-3458. DOI：10.3760/cma.j.cn112137-20210624-01430.
[16]	LINDNER G, BURDMANN E A, CLASE C M, et al. Acute hyperkalemia in the emergency department：a summary from a Kidney Disease：improving Global Outcomes conference[J]. Eur J Emerg Med，2020，27(5):329-337. DOI：10.1097/MEJ.0000000000000691.
[17]	HOPPE L K, MUHLACK D C, KOENIG W, et al. Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality：a systematic review and meta-analysis of observational studies[J]. Cardiovasc Drugs Ther，2018，32(2):197-212. DOI：10.1007/s10557-018-6783-0.
[18]	CHOI H Y, HA S K. Potassium balances in maintenance hemodialysis[J]. Electrolyte Blood Press，2013，11(1):9-16. DOI：10.5049/EBP.2013.11.1.9.
[19]	ESPOSITO P, CONTI N E, FALQUI V, et al. New treatment options for hyperkalemia in patients with chronic kidney disease[J]. J Clin Med，2020，9(8):E2337. DOI：10.3390/jcm9082337.
[20]	DEFRONZO R A, SHERWIN R S, FELIG P, et al. Nonuremic diabetic hyperkalemia. Possible role of insulin deficiency[J]. Arch Intern Med，1977，137(7):842-843. DOI：10.1001/archinte.137.7.842.
[21]	刘丽丽. 探讨高钾血症的心电图临床诊断表现及临床应用价值[J]. 当代医学，2020，26(11):140-141.
[22]	GALLOWAY C D, VALYS A V, SHREIBATI J B, et al. Development and validation of a deep-learning model to screen for hyperkalemia from the electrocardiogram[J]. JAMA Cardiol，2019，4(5):428-436. DOI：10.1001/jamacardio.2019.0640.
[23]	LITTMANN L, GIBBS M A. Electrocardiographic manifestations of severe hyperkalemia[J]. J Electrocardiol，2018，51(5):814-817. DOI：10.1016/j.jelectrocard.2018.06.018.
[24]	FORDJOUR K N, WALTON T, DORAN J J. Management of hyperkalemia in hospitalized patients[J]. Am J Med Sci，2014，347(2):93-100. DOI：10.1097/MAJ.0b013e318279b105.
[25]	刘旭，刁宗礼，刘文虎. 慢性肾脏疾病患者血钾控制的研究进展[J]. 临床和实验医学杂志，2018，17(1):109-111. DOI：10.3969/j.issn.1671-4695.2018.01.035.
[26]	PALMER B F, CARRERO J J, CLEGG D J, et al. Clinical management of hyperkalemia[J]. Mayo Clin Proc，2021，96(3):744-762. DOI：10.1016/j.mayocp.2020.06.014.
[27]	KALANTAR-ZADEH, FOUQUE. Nutritional management of chronic kidney disease[J]. N Engl J Med，2018，378(6):584-585. DOI：10.1056/NEJMc1715765.
[28]	RAMOS C I, GONZÁLEZ-ORTIZ A, ESPINOSA-CUEVAS A, et al. Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? [J]. Nephrol Dial Transplant，2021，36(11):2049-2057. DOI：10.1093/ndt/gfaa232.
[29]	ST-JULES D E, MARINARO M, GOLDFARB D S, et al. Managing hyperkalemia：another benefit of exercise in people with chronic kidney disease? [J]. J Ren Nutr，2020，30(5):380-383. DOI：10.1053/j.jrn.2019.10.001.
[30]	TRUHLÁR A, DEAKIN C D, SOAR J, et al. European Resuscitation Council Guidelines for Resuscitation 2015：section 4. Cardiac arrest in special circumstances[J]. Resuscitation，2015，95:148-201. DOI：10.1016/j.resuscitation.2015.07.017.
[31]	DAVEY M, CALDICOTT D. Calcium salts in management of hyperkalaemia[J]. Emerg Med J，2002，19(1):92-93. DOI：10.1136/emj.19.1.92-a.
[32]	HAREL Z, KAMEL K S. Optimal dose and method of administration of intravenous insulin in the management of emergency hyperkalemia：a systematic review[J]. PLoS One，2016，11(5):e0154963. DOI：10.1371/journal.pone.0154963.
[33]	BATTERINK J, CESSFORD T A, TAYLOR R A. Pharmacological interventions for the acute management of hyperkalaemia in adults[J]. Cochrane Database Syst Rev，2015. DOI：10.1002/14651858.cd010344.
[34]	SCHERR L, OGDEN D A, MEAD A W, et al. Management of hyperkalemia with a cation-exchange resin[J]. N Engl J Med，1961，264:115-119. DOI：10.1056/NEJM196101192640303.
[35]	EMMETT M, HOOTKINS R E, FINE K D, et al. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion[J]. Gastroenterology，1995，108(3):752-760. DOI：10.1016/0016-5085(95)90448-4.
[36]	LAUREATI P, XU Y, TREVISAN M, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease：a nationwide study[J]. Nephrol Dial Transplant，2020，35(9):1518-1526. DOI：10.1093/ndt/gfz150.
[37]	NOEL J A, BOTA S E, PETRCICH W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age[J]. JAMA Intern Med，2019，179(8):1025-1033. DOI：10.1001/jamainternmed.2019.0631.
[38]	COLBERT G B, PATEL D, LERMA E V. Patiromer for the treatment of hyperkalemia[J]. Expert Rev Clin Pharmacol，2020，13(6):563-570. DOI：10.1080/17512433.2020.1774363.
[39]	RAFIQUE Z, LIU M Y, STAGGERS K A, et al. Patiromer for treatment of hyperkalemia in the emergency department：a pilot study[J]. Acad Emerg Med，2020，27(1):54-60. DOI：10.1111/acem.13868.
[40]	WEIR M R, BAKRIS G L, BUSHINSKY D A, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors[J]. N Engl J Med，2015，372(3):211-221. DOI：10.1056/NEJMoa1410853.
[41]	BAKRIS G L, PITT B, WEIR M R, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease：the AMETHYST-DN randomized clinical trial[J]. JAMA，2015，314(2):151-161. DOI：10.1001/jama.2015.7446.
[42]	STAVROS F, YANG A, LEON A, et al. Characterization of structure and function of ZS-9，a K⁺ selective ion trap[J]. PLoS One，2014，9(12):e114686. DOI：10.1371/journal.pone.0114686.
[43]	LEVIEN T L, BAKER D E. Sodium Zirconium Cyclosilicate[J]. Hospital Pharmacy，2019，54(1):12-19.DOI：10.1177/0018578718817470.
[44]	KOSIBOROD M, RASMUSSEN H S, LAVIN P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia：the HARMONIZE randomized clinical trial[J]. JAMA，2014，312(21):2223-2233. DOI：10.1001/jama.2014.15688.
[45]	PEACOCK W F, RAFIQUE Z, VISHNEVSKIY K, et al. Emergency potassium normalization treatment including sodium zirconium cyclosilicate：a phase II，randomized，double-blind，placebo-controlled study （ENERGIZE）[J]. Acad Emerg Med，2020，27(6):475-486. DOI：10.1111/acem.13954.
[46]	SPINOWITZ B S, FISHBANE S, PERGOLA P E, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia：a 12-month phase 3 study[J]. Clin J Am Soc Nephrol，2019，14(6):798-809. DOI：10.2215/CJN.12651018.
[47]	KASHIHARA N, YAMASAKI Y, OSONOI T, et al. A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia[J]. Clin Exp Nephrol，2021，25(2):140-149. DOI：10.1007/s10157-020-01972-y.
[48]	FISHBANE S, FORD M, FUKAGAWA M, et al. A phase 3b，randomized，double-blind，placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia[J]. J Am Soc Nephrol，2019，30(9):1723-1733. DOI：10.1681/ASN.2019050450.
[49]	KOVESDY C P, ROWAN C G, CONRAD A, et al. Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients[J]. Kidney Int Rep，2019，4(2):301-309. DOI：10.1016/j.ekir.2018.10.020.